Optimi Health Corp. has announced the completion of its latest production batch of MDMA, a significant step for the company as it prepares for a Phase 3 clinical trial for treating post-traumatic stress disorder (PTSD) in Canada. This event is crucial as it marks the company's commitment to advancing mental health therapies using psychedelic substances.

On October 20, 2026, the company released a press statement detailing the completion of MDMA production at its GMP facility in Princeton, British Columbia. This batch is intended to support three key initiatives: a proposed Phase 3 clinical trial in Canada, a clinical trial in Israel in collaboration with the Multidisciplinary Association for Psychedelic Studies (MAPS), and a commercial export to Australia.

Background

Optimi Health Corp. operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. The company is publicly traded under the ticker OPTH on the Nasdaq exchange. It focuses on manufacturing and distributing GMP-grade psychedelic drug products aimed at mental health therapies. Recent filings show a proactive approach to expanding its operations and clinical trials.

What the Filing Says

The filing states, "On October 20, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference." This confirms the completion of the MDMA production and outlines the intended uses for the drug.

Impact

This development may significantly affect veterans and frontline workers in Canada, who are the primary focus of the upcoming Phase 3 trial. The trial aims to enroll up to 100 participants, providing them with MDMA-assisted therapy to evaluate its efficacy and safety in treating PTSD. Furthermore, the commercial supply to Australia could enhance access to MDMA-assisted therapy for patients there, as clinicians are authorized to prescribe the drug under specific regulatory frameworks.

What's Next

The filing does not specify what happens next, but the proposed Phase 3 trial is expected to begin in 2027, pending further regulatory approvals and preparations.